Subsidy Information and Financing Scheme MSHLApalutamide Tablet 60 mg 1) Apalutamide in combination with androgen deprivation therapy (ADT) for treating patients with hi... See all × MSHLApalutamide Tablet 60 mg 1) Apalutamide in combination with androgen deprivation therapy (ADT) for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). 2) Apalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC).
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 60 mg National Cancer Centre